REGENXBIO Reports Durable Long-Term Results for Gene Therapy Sura-vec

The five-year follow-up data from the Phase I/IIa trial demonstrated that patients with wet AMD maintained stable or improved vision after a single subretinal dose of sura-vec. Notably, these patients required fewer anti-VEGF injections compared to standard care, addressing the treatment burden that often leads to patient non-adherence and subsequent vision loss. No drug-related intraocular inflammation was observed in this cohort, bolstering the therapy's safety profile.

In parallel, results from the Phase II ALTITUDE trial showed positive outcomes for patients with non-proliferative diabetic retinopathy. At 2.5 years post-administration, 55% of participants achieved at least a two-step improvement on the Diabetic Retinopathy Severity Scale. REGENXBIO, in collaboration with AbbVie, plans to release topline data from the pivotal ATMOSPHERE and ASCENT studies in the fourth quarter of 2026. These ongoing trials involve over 1,200 participants and aim to further validate the potential of sura-vec to modify the underlying disease process in chronic retinal conditions.